Résilience - COVID-19 - Résilience - Coronavirus disease 2019

Clinical and biological characterization of mast cell ACTivation symptoms in long-COVID and genetic predisposition – ACT-LONG-COVID

Submission summary

Almost 10% of patients with COVID-19 have persistent symptoms after resolution of the infection. Some of these symptoms are related to complications of hospitalization or to specific symptoms of COVID-19. However, the majority of patients display symptoms not present at the time of the acute infection. The preliminary characterization of this condition shows a systemic disease with symptoms also found in the mast cell activation syndrome (MCAS). In addition, the presence of allergic manifestations prior to COVID-19 seems to be associated with the occurrence of long-COVID. MCAS is a condition described to be idiopathic, secondary to clonal mast cell disease (mastocytosis or KIT clonalitiy), or associated with an increased alpha-tryptase alpha/beta 1 (TPSAB1) gene copy number found in the hyper-alpha-tryptasemia (HAT). HAT is found in 5% of the general population versus 20-30% in mast cell activation diseases. We hypothesize that COVID-long is linked to a post-infectious MCAS that occurs in individuals with genetic predisposition. We aim to study the clinical and biological signs of MCAS as well as TPSAB1 gene copy number. If confirmed, treatments targeting mast cells could be a promising option of long COVID.

Project coordination

Olivier Hermine (INSTITUT DES MALADIES GÉNÉTIQUES (IHU))

The author of this summary is the project coordinator, who is responsible for the content of this summary. The ANR declines any responsibility as for its contents.

Partner

IMAGINE INSTITUT DES MALADIES GÉNÉTIQUES (IHU)

Help of the ANR 79,999 euros
Beginning and duration of the scientific project: May 2021 - 9 Months

Useful links

Explorez notre base de projets financés

 

 

ANR makes available its datasets on funded projects, click here to find more.

Sign up for the latest news:
Subscribe to our newsletter